The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-08 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
== Pharmacology == Vinblastine is a vinca alkaloid and a chemical analogue of vincristine. It binds tubulin, thereby inhibiting the assembly of microtubules. Vinblastine treatment causes M phase specific cell cycle arrest by disrupting microtubule assembly and proper formation of the mitotic spindle and the kinetochore, each of which are necessary for the separation of chromosomes during anaphase of mitosis. Toxicities include bone marrow suppression (which is dose-limiting), gastrointestinal toxicity, potent vesicant (blister-forming) activity, and extravasation injury (forms deep ulcers). Vinblastine paracrystals may be composed of tightly packed unpolymerized tubulin or microtubules. Vinblastine is reported to be an effective component of certain chemotherapy regimens, particularly when used with bleomycin and methotrexate in VBM chemotherapy for Stage IA or IIA Hodgkin lymphomas. The inclusion of vinblastine allows for lower doses of bleomycin and reduced overall toxicity with larger resting periods between chemotherapy cycles.
The Neanderthal skull has a flat and broad skullcap, rounded supraorbital torus (the buldge that forms the brow ridges), larger, wide orbits (eye sockets), a broad nose, mid-facial prognathism (the face projects far from the base of the skull), an "en bombe" (bomb-like) skull shape when viewed from the back, a fossa (depression) on the back of the skull below the level of the inion (suprainiac fossa), and an occipital bun (bony projection) at the back of the skull. Like those of other archaic humans, their jaws lack a true chin. The Neanderthal braincase averages 1,640 cm3 (100 cu in) for males and 1,460 cm3 (89 cu in) for females, which is significantly larger than the averages for all 147 homonids studied. The largest Neanderthal brain, Amud 1, was calculated to be 1,736 cm3 (105.9 cu in), one of the largest ever recorded in humans. Neanderthal brain organisation differs in areas related to cognition and language, which may be implicated in the comparative simplicity of Neanderthal behaviour to Cro-Magnons in the archaeological record. Neanderthals had large and wide noses, probably an adaptation to warm greater quantities of cold air to fuel their assumed heightened metabolism and activity levels. A large nose does not necessarily equate to a better sense of smell, and neurologically, because the olfactory bulbs are smaller, Neanderthals may have had a poorer sense of smell and olfactory memory than modern humans.
Starting on October 16, 1963, the Ad Hoc Committee to End Discrimination organized pickets and sit-ins at the Mel's Drive-In locations in San Francisco, Oakland, and Berkeley over the fact that while the restaurant would serve food to African Americans and hired them as cooks, they were not allowed to work "up front" where they could be seen by white customers. More than 100 protesters were arrested. The picketing ended when Harold Dobbs, Mel's Drive-In co-founder who was serving as a San Francisco City supervisor at the time, settled with the protesters and began to allow black workers upfront.
ELABELA (ELA, Apela, Toddler) is a hormonal peptide that in humans is encoded by the APELA gene. Elabela is one of two endogenous ligands for the G-protein-coupled APLNR receptor. Ela is secreted by certain cell types including human embryonic stem cells. It is widely expressed in various developing organs such as the blastocyst, placenta, heart, kidney, endothelium, and is circulating in human plasma.
Sources: en.wikipedia.org
No. 237 Squadron, based in Kenya since before the start of the war, had expanded to 28 officers and 209 other ranks by March 1940. By mid-1940, most of the officers and men Southern Rhodesia had sent overseas were in Kenya, attached to various East African formations, the King's African Rifles (KAR), the RWAFF, or to the colony's own Medical Corps or Survey Unit. The Southern Rhodesian surveyors charted the previously unmapped area bordering Abyssinia and Italian Somaliland between March and June 1940, and the Medical Corps operated No. 2 General Hospital in Nairobi from July. A company of coloured and Indian-Rhodesian transport drivers was also in the country, having arrived in January. The first Southern Rhodesian contingent despatched to North Africa and the Middle East was a draft of 700 from the Rhodesia Regiment who left in April 1940. No white Rhodesian force of this size had ever left the territory before. They were posted to a variety of British units across Egypt and Palestine. The largest concentration of Rhodesian soldiers in North Africa belonged to the King's Royal Rifle Corps (KRRC), whose connections with the colony dated back to World War I. Several Rhodesian platoons were formed in the KRRC's 1st Battalion in the Western Desert. A company of men from the Southern Rhodesian Signal Corps was also present, operating in tandem with the British Royal Corps of Signals.
A fusee is a practical necessity in watches using a verge escapement, and can also provide considerable benefit with a lever escapement and other high precision types of escapements (Hamiltons WWII era Model 21 chronometer used a fusee in combination with a detent escapement). Keywind watches are also commonly seen with conventional going barrels and other types of mainspring barrels, particularly in American watchmaking.
Roscovitine is an inhibitor of cyclin-dependent kinase. It increases the current of calcium in neostriatal interneurons by slowing the deactivation of the channel. Also, roscovitine can either act as an agonist or antagonist for the P-type calcium channels in the presynaptic membrane. Isoprenaline is a β-adrenoceptor agonist and it causes an increase in P-type calcium channel current. Isoprenaline acts through a cAMP signaling pathway. Eliprodil and antazoline are NMDA receptor antagonists and act to block P-type channels. Eliprodil can decrease P-type channel currents in the Purkinje neurons in the cerebellum. Dodecylamine can only block P-type channels when they are in the open state. Ethanol can block P-type channels when at a high enough concentration. The blocking of the P-type channels could be the reason for ataxia when drinking alcohol.
Sources: en.wikipedia.org
== Health claims == By the early 2010s, "bone broth" had become a popular health food trend, due to the resurgence in popularity of dietary fat over sugar, and interest in "functional foods" to which "culinary medicinals" such as turmeric and ginger could be added. Bone broth bars, bone broth home delivery services, bone broth carts, and bone broth freezer packs grew in popularity in the United States. The fad was heightened by the 2014 book Nourishing Broth, in which authors Sally Fallon Morell and Kaayla T. Daniel claim that the broth's nutrient density has a variety of health effects. There is no scientific evidence to support many of the claims made for bone broth.
=== Nonmedical use === Dexamethasone is given to prostituted Bangladeshi children, causing weight gain aimed at making them appear older and healthier to customers and police. Dexamethasone and most glucocorticoids are banned by sporting bodies including the World Anti-Doping Agency.
Securities and Exchange Commission prosecutor and Republican candidate for New York's 1st congressional district Robert Karem (2000), assistant secretary of defense for international security affairs and former acting under secretary of defense for policy David Segal (2001), member of the Rhode Island House of Representatives Robby Mook (2002), political campaign strategist and campaign manager for Virginia governor Terry McAuliffe, former executive director of Democratic Congressional Campaign Committee; campaign manager for Hillary Clinton presidential campaign, 2016 Sam Arora (2003), member of the Maryland House of Delegates 2011–2015 Cyrus Habib (2003), lieutenant governor of Washington, first and only Iranian American elected to a state office in the U.S. Adam Jentleson (2003), former deputy chief of staff to Harry Reid and columnist of GQ Nikil Saval (2005), former editor of N+1, member of the Pennsylvania State Senate Josie Raymond (2007), member of the Kentucky House of Representatives from the 31st district Ruthzee Louijeune (2008), president of the Boston City Council Sara Jacobs (2011), member of the United States House of Representatives for California's 53rd congressional district, granddaughter of Qualcomm founder Irwin M.
The Sindh Institute of Urology & Transplantation (SIUT) is a tertiary referral hospital specialized in nephrology, urology, dialysis and kidney transplant. It is located in Karachi, Sindh, Pakistan. SIUT was founded by Adeebul Hasan Rizvi and it is one of the largest kidney disease center in Pakistan.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.